ACE and peripheral arterial disease: In 2016, the use of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin-receptor blockers (ARBs) is recommended to reduce the risk of cardiovascular events in patients with established PAD, with the level of evidence changed from (IIa B) to (IIa A) in 2016.